BlackRock’s European IB1T ETP Tops $1.1B; Holds 14,200 BTC
BlackRock’s European iShares Bitcoin ETP (IB1T) exceeded $1.1 billion in assets and held about 14,200 BTC as of May 4, 2026.
BlackRock’s European iShares Bitcoin ETP, trading as IB1T, exceeded $1.1 billion in assets under management and held roughly 14,200 BTC as of May 4, 2026. The fund is listed on Euronext Amsterdam and other European exchanges and launched in March 2025.
IB1T was created to give non-U.S. institutional investors regulated exposure to spot bitcoin. The fund reached more than $1.1 billion after about 14 months on the market.
IB1T operates within the EU’s Markets in Crypto-Assets (MiCA) framework and through established ETP exchange structures, rather than through the U.S. Securities and Exchange Commission process that enabled BlackRock’s U.S. product. In the United States, BlackRock’s iShares Bitcoin Trust, IBIT, is the largest spot bitcoin product by assets. IBIT drew $824 million in a single week in late April 2026.
On May 4, 2026, bitcoin traded above $80,000 for the first time in weeks. Trading that day was partly driven by institutional demand that absorbed more than 500% of the daily mined bitcoin supply. Across its global bitcoin products, BlackRock held about 773,990 BTC.
IB1T’s holdings and AUM figures are calculated from market prices and fund flows as of May 4, 2026. The ETP gives asset managers, pension funds and other institutional investors a regulated vehicle to gain direct exposure to bitcoin without buying and storing the asset themselves.
The European ETP complements BlackRock’s U.S. offering and increases the firm’s institutional bitcoin product availability across jurisdictions.
The material on GNcrypto is intended solely for informational use and must not be regarded as financial advice. We make every effort to keep the content accurate and current, but we cannot warrant its precision, completeness, or reliability. GNcrypto does not take responsibility for any mistakes, omissions, or financial losses resulting from reliance on this information. Any actions you take based on this content are done at your own risk. Always conduct independent research and seek guidance from a qualified specialist. For further details, please review our Terms, Privacy Policy and Disclaimers.








